References

1. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-286.

2. Schweitzer ME, Fort J. Cost-effectiveness of MR imaging in evaluating polymyositis. AJR 1995;165:1469-1471.

3. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol 1993; 100:124S-127S.

4. Cosnes A, Amaudric F, Gherardi R, Verroust J, Wechsler J, Revuz J, Roujeau JC. Dermatomyositis without muscle weakness—long-term follow-up of 12 patients without systemic corticosteroids. Arch Dermatol 1995;131:1381-1385.

5. Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis—analysis of 32 cases. J Rheumatol 1992;19:1385-1389.

6. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991;325:1487-1498.

7. Gherardi RK, Coquet M, Cherin P, et al. Macrophagic fasciitis: an emerging entity. Lancet 1998;352:347-352.

8. Dalakas MC. Clinical benefits and immunopatholog-ical correlates of intravenous immune globulin in the treatment of inflammatory myopathies. Clin Exp Immunol 1996;104(suppl l):55-60.

9. Plötz PH, Rider LG, Targoff IN, Raben N, O'Hanlon TP, Miller FW. Myositis: immunologic contributions to understanding cause, pathogenesis, and therapy. Ann Int Med 1995;122:715-724.

10. Love LA, Leff RL, Fräser DD, Targoff IN, Dalakas M, Plötz PH, Miller FW. A new approach to the classification of idiopathic inflammatory myopathy— myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 1991;70:360-374. Stertz G. Polymyositis. Berl Klin Wochenschr 1916;53:489.

Lakhampal S, Bunch TW, Ilstrup DM, Melton LJ III. Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 1986;61:645-653.

Lyon MG, Bloch DA, Hollak B, Fries JF. Predisposing factors in dermatomyositis-polymyositis: results of a nationwide survey. J Rheumatol 1989;16:1218-1224. Bernard P, Bonnetblanc JM. Dermatomyositis and malignancy. J Invest Dermatol 1993; 100:S 128-S132. Bonnetblanc JM, Bernard P, Fayol J. Dermatomyositis and malignancy. A multicenter cooperative study. Dermatologica 1990;180:212-216. Callen JP. Myositis and malignancy. Clin Rheum Dis 1984, 10:117-130.

Callen JP. Relationship of cancer to inflammatory muscle diseases: dermatomyositis, polymyositis, and inclusion body myositis. Rheum Dis Clin North Am 1994;20:943-953.

Sigurgeirsson B, Lindelof B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992;326:363-367.

Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995;22:1300-1303. Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol 1996;14:263-274 Rose C, Hatron PY, Brouillard M, et al. Signes prédictifs de cancers au cours de la dermatomyosite. Etude de 29 observations. Rev Med Int 1994;15:19-24. Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I, Gur H, Ehrenfeld M. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthrit Rheumatol 1998;27:319-324. Marie I, Hatron PY, Levesque H, Hachulla E, Hel-lot MF, Michon-Pasturel U, Courtois H, Devulder B. Influence of age on characteristics of polymyositis and dermatomyositis in adults. Medicine (Baltimore) 1999;78:139-147.

Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994;21:1855— 1859.

Schulman P, Kerr LD, Spiera H. A reexamination of the relationship between myositis and malignancy. J Rheumatol 1991;18:1689-1692.

26. Barnes BE. Dermatomyositis and malignancy. A review of the literature. Ann Int Med 1976;84:68-76.

27. Cherin P, Piette JC, Herson S, et al. Dermatomyositis and ovarian cancer: a report of 7 cases and literature review. J Rheumatol 1993;20:1897-1899.

28. Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine 1994;73:153-160.

29. Whitmore SE, Anhalt GJ, Provost TT, Zacur HA, Hamper UM, Hhlzlsouer KJ, Rosenshein NB. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecol Oncol 1997;65:241-244.

30. Kubo M, Sato S, Kitahara H, Tsuchida T, Tamaki K. Vesicle formation in dermatomyositis associated with gynecologic malignancies. J Am Acad Dermatol 1996;34:391-394.

31. Peng JC, Sheen TS, Hsu MM. Nasopharyngeal carcinoma with dermatomyositis: analysis of 12 cases. Arch Otolaryngol Head Neck Surg 1995;121:1298-1301.

32. Fung WK, Chan HL, Lam WM. Amyopathic dermatomyositis in Hong Kong—association with nasopharyngeal carcinoma. Int J Dermatol 1998;37:659-663.

33. Leow YH, Goh CL. Malignancy in adult dermatomyositis. Int J Dermatol 1997;36:904-907.

34. Osman Y, Narita M, Kishi K, Fujiwara H, Fukuda T, Koike T, Shibata A. Amyopathic dermatomyositis associated with transformed malignant lymphoma. Am J Med Sciences 1996, 311:240-242.

35. Creange A, Theodorou I, Sabourin JC, Vital C, Farcet JP, Gherardi RK. Inflammatory neuromuscular disorders associated with chronic lymphoid leukemia:Evidence for clonal B cells within muscle and nerve. J Neurol Sci 1996, 137: 35-41.

36. Ytterberg SR, Roelofs RI, Mahowald ML. Inclusion body myositis and renal cell carcinoma—report of two cases and review of the literature. Arthrit Rheumatol 1993;36:416-421.

37. Sherry DD, Haas JE, Milstein JM. Childhood polymyositis as a paraneoplastic phenomenon. Pedi-atr Neurol 1993;9:155-156.

38. Guiziou C, Lebreton C, Kaplan G, Vigneron AM, Kahn MF. Les sclerodermatomyosites. A propos de 13 observations. Rev Rheumatol 1987;54:457-461.

39. Tymms KE, Webb J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J Rheumatol 1985;12:1140-1148.

40. Dawkins MA, Jorizzo JL, Walker FO, Albertson D, Sinai SH, Hinds A. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol 1998;38:397-404.

41. Grau JM, Miro O, Pedrol E, Casademont J, Masanes F, Herrero C, Haussman G, Urbano-Marquez A. Inter-

stitial lung disease related to dermatomyositis. Com- 55. parative study with patients without lung involvement. J Rheumatol 1996;23:1921-1926.

42. Cox NH, Lawrence CM, Langtry JA, Ive FA Dermatomyositis. Disease associations and an evalúa- 56. tion of screening investigations for malignancy. Arch Dermatol 1990, 126:61-65.

43. Basset-Seguin N, Roujeau JC, Gherardi R, Guillaume JC, Revuz J, Touraine R. Prognostic factors and predictive signs of malignancy in adult dermatomyositis. 57. A study of 32 cases. Arch Dermatol 1990; 126:633637.

44. Gallais V, Crickx B, Beiaich S. Lésions nécrotiques cutanées au cours de la dermatomyosite de 58. l'adulte:un signe prédictif de cancer? Presse Medícale 1995;24:1907.

45. Mautner GH, Grossman ME, Silvers DN, Rabinowitz

A, Mowad CM, Johnson BL Jr. Epidermal necrosis 59. as a predictive sign of malignancy in adult dermatomyositis. Cutis 1998;61:190-194.

46. Roselino AM, Souza CS, Andrade JM, Tone LG, Soares FA, Llorach-Velludo MA, Foss NT. Der- 60. matomyositis and acquired ichthyosis as paraneoplastic manifestations of ovarian tumor. Int J Dermatol 1997;36:611-614. 61.

47. Fudman EJ, Schnitzer TJ Dermatomyositis without creatine kinase elevation. Am J Med 1986;80:329-332.

48. Whitmore SE, Watson R, Rosenshein NB, Provost

TT. Dermatomyositis sine myositis: association with 62. malignancy. J Rheumatol 1996;23:101-105.

49. Matsuno O, Matsumoto T, Miyazaki E, Nakagawa H, Kumamoto T, Tsuda T. Pyomyositis associated with bacteroides fragilis in a patient with multiple 63. myeloma. Am J Trop Med Hyg 1998;59:42^14.

50. Carsons S The association of malignancy with rheumatic and connective tissue diseases. Semin On- 64. col 1997;24:360-372.

51. Zuckner J Drug-related myopathies. Rheum Dis Clin 65. North Am 1994;20:1017-1032.

52. Esteva-Lorenzo FJ, Janik JE, Fenton RG, Emslie-Smith A, Engel AG, Longo DL. Myositis associated with interleukin-2 therapy in a patient with metastatic 66. renal cell carcinoma. Cancer 1995;76:1219-1223.

53. Rowinsky EK, Chaudhry V, Forastiere AA, et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating fac-tonneuromuscular toxicity is dose-limiting. J Clin

Oncol 1993;11:2010-20. 67

54. Crayton H, Bohlmann T, Sufit R, Graziano FM. Drug Induced Polymyositis Secondary to Leuprolide Acetate (Lupron) Therapy for Prostate Carcinoma. Clin 68. Exp Rheumatol 1991;9:525-528.

Arai H, Tanaka M, Ohta K, Kojo T, Niijima K, Imawari M. Symptomatic myopathy associated with interferon therapy for chronic hepatitis C. Lancet 1995;345:582.

Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. QJM 1998;91:393-399.

Falcone A, Bodenizza CA, Musto P, Carotenuto M. Symptomatic myopathy during interferon alpha therapy for chronic myelogenous leukemia. Leukemia 1998; 12:1329.

Bahadoran P, Castanet J, Lacour JPH, et al. Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases. Br J Dermatol 1996;134:1161-1163.

Kirby B, Rogers S Hydroxyurea-induced dermopa-thy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. J Am Acad Dermatol 1998;38:781-782.

Parker P, Chao NJ, Ben-Ezra J, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine 1996;75:279-285. Kamel OW, Van de Rijn M, Weiss LM, et al. Reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Eng J Med 1993;328:1317-1321.

Serratrice G. Dermatopolymyosites. In: Kahn MF, Peltier AP, Meyer O, Piette JC, eds., Les maladies systémiques. Paris: Flammarion Médecine-Sciences, 1991;473^97.

O'Gradaigh D, Merry P. Tumour markers in dermatomyositis: useful or useless? Br J Rheumatol 1998;37:914.

Till SH, Jones AC. Dermatomyositis—how far to go! Ann Rheum Dis 1998;57:198-200. Le Thi Huong Du, Mohattane A, Piette JC ,et al. Spécificité du marqueur tumoral CA 125. Etude de 328 observations de médecine interne. Presse Med 1988;17:2287-2291.

Chérin P, Herson S, Crevon MC, Hauw JJ, Cervera P, Galanaud P, Emilie D. Mechanisms of lysis by activated cytotoxic cells expressing perforin and granzyme-B genes and the protein TIA-1 in muscle biopsies of myositis. J Rheumatol 1996;23:1135— 1142.

Tews DS, Goebel HH. Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996;55:342-347. Tateyama T, Nagano I, Yoshioka M, Chida K, Naka-mura S, Itoyama Y. Expression of tumor necrosis factor-alpha in muscles of polymyositis. J Neurol Sci 1997;146:45-51.

69. Ilia I, Gallardo E, Gimeno R, Serrano C, Ferrer I, Juarez C. Signal transducer and activator of transcription 1 in human muscle: implications in inflammatory myopathies. Am J Pathol 1997; 151:81— 8.

70. Leff RL, Love LA, Miller FW, Greenberg SJ, Klein EA, Dalakas MC, Plotz PH. Viruses in idiopathic inflammatory myopathies—absence of candidate viral genomes in muscle. Lancet 1992;339:1192-1195.

71. Pachman LM, Litt DL, Rowley AH, et al. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis. Arthrit Rheumatol 1995;38:1513-1518.

72. Nakamura S, Umeda T, Yokozeki H, Katayama I, Nishioka K. Possible involvement of tumour-derived interleukin-6 in dermatomyositis associated with cervical squamous cell carcinoma. Br J Dermatol 1997;136:475-476.

73. Hall TC. Paraneoplastic syndromes:mechanisms. Semin Oncol 1997;24:269-276.

74. Scott AM. Clinical promise of tumour immunology. Lancet 1997;349(suppl II): 19-22.

75. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998;95:279-289.

© 2000 Elsevier Science B.V. All rights reserved.

Cancer and Autoimmunity

Y. Shoenfeld and M. E. Gershwin, editors

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment